arrow
N

Nadège Corradini

centre leon berard
H指数:36
被引数:4,815

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO)

青少年和年轻成人横纹肌肉瘤的见解:法国儿科肿瘤学会(SFCE)恶性间质瘤(MMT)委员会和法国肉瘤组(GSF-GETO)的综合性临床研究

2026-09-010
OAAI
Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort

NF1相关性和散发性恶性周围神经鞘瘤的临床决定因素、诊断复杂性和分子异质性:一项25年转诊中心队列研究

2026-07-080
PRE
Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience

拉罗替尼在儿童、青少年和年轻成人TRK融合实体瘤患者中的真实世界经验:SACHA-France研究经验

2026-06-210
PRE
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study

伊达沙纳替林联合化疗或维奈克拉用于复发/难治性实体瘤的儿科及青年成年患者(iMATRIX Idasa):一项多中心、多臂I/II期研究的结果

2025-12-110
PRE
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

对于新诊断的多发性转移性尤因肉瘤患者,采用序贯多模式治疗方法的临床价值:法国前瞻性CombinaiR3 II期试验结果

2025-11-170
PRE
NTRK-Rearranged Mesenchymal Tumors and Related Tumors in Children, Adolescents and Young Adults: a Clinico-Pathologic and Molecular Characterization
2025-03-010
PRE
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
CANCER
IF5.1
2025-02-110
PRE
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
2024-10-080
PRE
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Updated data from the iMATRIX Alectinib phase I/II open-label, multi-center study
2024-09-050
PRE
Whole genome sequencing can reproduce all standard-of-care diagnostics for childhood cancer: Results from two national systems
2024-09-050
PRE
Alveolar soft part sarcomas in young patients: The French national NETSARC plus network experience
EJSO
IF2.9
2024-09-011
PRE
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study

Alectinib在患有ALK融合的实体或CNS肿瘤的儿童和青少年中的应用: 来自iMATRIX Alectinib I/II期开放标签,多中心研究的数据

2024-04-050
PRE
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS
2024-04-011
PRE
Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers
2023-12-015
OAAI
Pediatric Tumors and Developmental Anomalies: A French Nationwide Cohort Study
2023-08-012
OAAI
The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas
2023-07-071
OAAI
Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group
CANCER
IF5.1
2023-04-217
OAAI
Phase I/II study of the PARP inhibitor olaparib in combination with irinotecan in children with advanced malignancies: arm D of the AcSe-ESMART trial
2023-04-145
PRE